TIMP2 Cancer Research Results

TIMP2, Tissue Inhibitor of Metalloproteinases-2: Click to Expand ⟱
Source:
Type:
TIMP-2 has been shown to have distinct effects on cancer progression compared to TIMP-1. Research has suggested that TIMP-2 may have anti-tumor effects in certain types of cancer, including:
• Inhibiting tumor growth: TIMP-2 has been shown to inhibit the growth of tumor cells in vitro and in vivo.
High levels of TIMP-2 have been associated with better prognosis and improved survival in some cancers.
High levels of TIMP-2 have been associated with better prognosis and improved survival in some cancers.
High TIMP-2 expression: Breast, Lung, colorectal, Prostrate.
Low TIMP-2 expression: Ovarian, Pancreatic, Gastric.
Scientific Papers found: Click to Expand⟱
247- AL,    Allicin inhibits the invasion of lung adenocarcinoma cells by altering tissue inhibitor of metalloproteinase/matrix metalloproteinase balance via reducing the activity of phosphoinositide 3-kinase/AKT signaling
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
MMP2↓, MMP9↓, TIMP1↑, TIMP2↑, p‑Akt↓, PI3K/Akt↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
3167- Ash,    Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo
- in-vitro, MM, H226
TumCP↓, cMyc↓, cFos↓, cJun↓, TIMP2↑, Vim↓, ROS↑, BAX↑, IKKα↑, Casp3↑, cl‑PARP↑,
5591- BetA,    Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment
- Review, BC, NA
BioAv↓, BioAv↑, selectivity↑, eff↑, angioG↓, *antiOx↑, *Inflam↓, MMP↓, Bcl-2↓, BAX↑, Casp9↑, Casp3↑, GRP78/BiP?, ER Stress↑, PERK↑, CHOP↑, ChemoSen↑, SESN2↑, ROS↑, MOMP↓, MAPK↑, Cyt‑c↑, AIF↑, STAT3↓, FAK↓, TIMP2↑, TumCMig↓, TumCI↓, Sp1/3/4↓, TumCCA↑, DNAdam↑,
2742- BetA,    Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
- in-vitro, BC, MDA-MB-231 - in-vivo, BC, 4T1 - in-vitro, BC, MCF7
tumCV↓, TumCMig↓, TumCI↓, STAT3↑, FAK↓, MMPs↓, MMP2↓, MMP9↓, TIMP2↑,
2746- BetA,    Betulinic acid induces apoptosis and inhibits metastasis of human colorectal cancer cells in vitro and in vivo
- in-vitro, CRC, HCT116 - in-vivo, CRC, NA
TumCG↓, BAX↑, Bcl-2↓, ROS↑, MMP↓, TIMP2↑, TumVol↓,
6542- BSB,    Health Benefits, Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of α-Bisabolol
- Review, Var, NA - Review, Park, NA - Review, AD, NA
AntiCan↑, *neuroP↑, *cardioP↑, *AntiBio↑, *BioAv↑, *toxicity↓, *BioAv↑, *motorD↑, *SOD↑, *Catalase↑, *Keap1↑, *MDA↓, *GSH↑, *IL1β↓, *IL6↓, *TNF-α↓, *iNOS↓, *COX2↓, *lipid-P↓, *Cyt‑c↓, *ROS↓, *MMP↑, *antiOx↑, *AChE↓, *Apoptosis↓, *BAX↓, *Casp3↓, *Bcl-2↑, *BACE↓, *BChE↓, *eff↑, *Aβ↓, *ATP↑, RadioS↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Apoptosis↑, PARP↑, BAX↑, BID↑, NF-kB↑, Fas↑, EGFR↑, TIMP2↑, XIAP↓, COX2↓, Bak↓, Bcl-2↓, P53↑, HER2/EBBR2↓, FGF↓, CEA↓, Akt↓, TumCCA↑, *Imm↑, *CD4+↑, *CD8+↑, *BBB↑, *Pain↓, *cardioP↑, *TBARS↓, *SOD↑, *Catalase↑, *GSH↑, *AntiBio↑, *AntiFungal↑, *GastroP↑, *RenoP↑, *creat↓, *uricA↓, *Inflam↓, *iNOS↓, *COX2↓, *TNF-α↓, *IL6↑, *MMP13↓,
5894- CAR,    Targeting Gastrointestinal Cancers with Carvacrol: Mechanistic Insights and Therapeutic Potential
- Review, Var, NA
AntiCan↑, Apoptosis↑, Inflam↓, angioG↓, TumMeta↓, selectivity↑, BioAv↑, ChemoSen↑, Dose↝, TumCP↓, hepatoP↑, Casp3↑, Casp9↑, Bcl-2↓, ROS↑, GSH↓, BAX↑, Casp7↑, Casp8↑, Cyt‑c↑, Fas↑, FADD↑, P53↑, Bcl-2↓, TumMeta↓, TumCMig↓, TumCI↓, E-cadherin↑, TIMP2↑, TIMP3↑, N-cadherin↓, ZEB2↓, *lipid-P↓, *AST↓, *ALAT↓, *ALP↓, *LDH↓, *SOD↑, *Catalase↑, *GPx↑, *GSR↑, selectivity↑, cl‑PARP↑, ERK↓, p38↑, OS↑, AFP↓, COX2↓, VEGF↓, PCNA↓, Ki-67↓, TNF-α↓, BioAv↓,
2790- CHr,    Chrysin: Pharmacological and therapeutic properties
- Review, Var, NA
*hepatoP↑, *neuroP↓, *ROS↓, *cardioP↑, *Inflam↓, eff↑, hTERT/TERT↓, cycD1/CCND1↓, MMP9↓, MMP2↓, TIMP1↑, TIMP2↑, BioAv↑, HK2↓, ROS↑, MMP↓, Casp3↑, ADP:ATP↑, Apoptosis↑, ER Stress↑, UPR↑, GRP78/BiP↝, eff↑, Ca+2↑,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
6388- Eug,    Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review
- Review, Var, NA
Dose↝, AntiCan↑, *Inflam↓, *cardioP↑, *neuroP↑, angioG↓, TumMeta↓, *BioAv↑, *eff↑, *toxicity↝, antiNeop↑, TumCCA↑, Apoptosis↑, *antiOx↑, *lipid-P↓, *ROS↓, *SOD↑, *Catalase↑, *GSTs↑, *GPx↑, *iNOS↓, *COX2↓, *IL6↓, *TNF-α↓, *AntiArt↑, *Bacteria↓, TumAuto↑, PI3K↓, Akt↓, FOXO3↝, BAX↑, mTOR↓, NF-kB↓, P53↑, TumCG↓, CSCs↓, CD44↓, EpCAM↓, NOTCH1↓, OCT4↓, Bcl-2↓, PDK1↓, HER2/EBBR2↓, BAD↓, cycD1/CCND1↓, ROS↑, Casp3↑, selectivity↑, MMP2↓, MMP9↓, TIMP1↑, VEGF↓, VEGFR1↓, RECK↑, TIMP2↑, DNAdam↑, MMP↓, Thiols↓, PARP↑, *Pain↓, E2Fs↓, survivin↓,
6336- Eug,    Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG
- in-vivo, GC, NA
Apoptosis?, Bcl-2↓, Cyt‑c↝, Casp↑, TumCI↓, angioG↓, MMPs↓, VEGF↓, VEGFR1↓, TIMP2↑, RECK↑,
6330- Eug,    Molecular Mechanisms of Action of Eugenol in Cancer: Recent Trends and Advancement
- Review, Var, NA
TumCD↑, TumCCA↑, AntiCan↑, Apoptosis↑, angioG↓, TumCI↓, TumMeta↓, ChemoSen↑, ALDH↓, NF-kB↓, IL6↓, IL8↓, BAX↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, Bcl-2↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Snail↓, E-cadherin↑, SOX2↓, ROS↑, PCNA↓, MMP1↓, Cyt‑c↑, LDH↑, CSCs↓, OCT4↓, NOTCH1↓, EpCAM↓, CD44↓, HER2/EBBR2↓, VEGF↓, TIMP2↑, eff↑, Ca+2↑, TumVol↓, DNAdam↑, GSH↓, H2O2↑, lipid-P↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
3267- Lyco,    Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways
- in-vitro, Nor, HUVECs
*VEGF↓, *MMP2↓, *uPA↓, *Rac1↑, *TIMP2↑, *p38↓, *Akt↓, *angioG↓,
4782- Lyco,    New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, TumCI↓, TumCA↓, ROS↓, MMP2↓, MMP7↓, MMP9↓, VEGF↓, E-cadherin↑, TIMP1↑, TIMP2↑, BioAv↝, *IL12↓, *TNF-α↓, *IL1↓, *IL1β↓, *IL6↓, COX2↓, iNOS↓, *radioP↑, NF-kB↓, survivin↓, Casp3↑, Bax:Bcl2↑,
4788- Lyco,    Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review)
- Review, Var, NA
AntiCan↑, ChemoSen↑, chemoP↑, Dose↝, BioAv↑, BioAv↑, BioAv↓, cardioP↑, AntiDiabetic↑, hepatoP↑, neuroP↑, MAPK↓, MMP2↓, MMP9↓, TIMP1↑, TIMP2↑,
3745- MFrot,  MF,    The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer's disease
- Review, AD, NA
*neuroP↑, *ROS↓, *Inflam↓, *5HT↑, *cFos↑, *Aβ↓, *memory↑, *BDNF↑, *Ach↑, *AChE↓, *cognitive↑, *BDNF↑, *NGF↑, *β-catenin/ZEB1↑, *p‑Akt↓, *mTOR↓, *MMP1↓, *MMP9↓, *MMP-10↓, *TIMP1↑, *TIMP2↑,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
6491- Nimb,    Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells
- Review, PC, NA
eff↑, uPA↓, uPAR↓, p‑EGFR↓, VEGFR1↓, NF-kB↓, IKKα↓, MMP2↓, MMP9↓, TIMP2↑, TumCP↓, IGFR↓, Akt↓, ERK↓, TumCCA↓, BAX↑, BAD↑, FasL⇅, Cyt‑c↑, EPR↑,
6492- Nimb,    Review on Molecular and Chemopreventive Potential of Nimbolide in Cancer
- Review, NA, NA
Apoptosis↑, TumCCA↑, TumCP↓, TumCI↓, angioG↓, TumMeta↓, PTEN↑, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, IKKα↓, CXCR2↓, CXCR4↓, Bcl-2↓, COX2↓, MMP9↓, VEGF↓, TIMP2↑, chemoPv↑, ROS↑, DR4↑, P53↑, BAX↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Mcl-1↓, XIAP↓, survivin↓, FasL↑, FADD↑, EGFR↓, MMPs↓,
3347- QC,    Recent Advances in Potential Health Benefits of Quercetin
- Review, Var, NA - Review, AD, NA
*antiOx↑, *ROS↓, *Inflam↓, TumCP↓, Apoptosis↑, *cardioP↑, *BP↓, TumMeta↓, MDR1↓, NADPH↓, ChemoSen↑, MMPs↓, TIMP2↑, *NLRP3↓, *IFN-γ↑, *COX2↓, *NF-kB↓, *MAPK↓, *CRP↓, *IL6↓, *TNF-α↓, *IL1β↓, *TLR4↑, *PKCδ↓, *AP-1↓, *ICAM-1↓, *NRF2↑, *HO-1↑, *lipid-P↓, *neuroP↑, *eff↑, *memory↑, *cognitive↑, *AChE↓, *BioAv↑, *BioAv↑, *BioAv↑, *BioAv↑, *BioAv↑,
3371- QC,    Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways
- in-vitro, GBM, T98G
TIMP2↑, TumCG↓, TumCMig↓, Apoptosis↑, TumCCA↑, MMP↓, ROS↑, Bax:Bcl2↑, cl‑Casp9↑, cl‑Casp3↑, DNAdam↑, γH2AX↑, MGMT↓, cl‑PARP↑,
3079- RES,    Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action
- Review, Var, NA
angioG↓, TumMeta↓, ChemoSen↑, NADPH↑, SIRT1↑, NF-kB↓, NLRP3↓, Dose↝, COX2↓, MMP9↓, PGE2↓, TIMP1↑, TIMP2↑, Sp1/3/4↓, p‑JNK↓, uPAR↓, ROS↓, CXCR4↓, IL6↓, Gli1↓, *ROS↓, *GSTs↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *GSH↑, eff↑, eff↑, eff↑,
3086- RES,    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,
3332- SIL,    Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2
- in-vitro, Lung, A549
*antiOx↑, *hepatoP↑, MMP2↓, uPA↓, TIMP2↑,
3131- VitC,    Antioxidant Vitamin C attenuates experimental abdominal aortic aneurysm development in an elastase-induced rat model
- in-vivo, Nor, NA
*MMP2↓, *MMP9↓, *TNF-α↓, *IL1β↓, *TIMP2↑, *TIMP1↓, *antiOx↑, *Inflam↓,

Showing Research Papers: 1 to 28 of 28

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 28

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

CYP1A1↑, 1,   Ferroptosis↑, 1,   GSH↓, 2,   H2O2↑, 1,   HO-1↓, 1,   lipid-P↓, 1,   lipid-P↑, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↓, 2,   ROS↑, 15,   Thiols↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↑, 2,   AIF↑, 1,   CDC2↓, 1,   CDC25↓, 1,   MMP↓, 5,   Raf↓, 1,   e-Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 3,   p‑cMyc↑, 1,   GLO-I↓, 1,   HK2↓, 1,   LDH↑, 1,   NADPH↓, 1,   NADPH↑, 1,   PDK1↓, 1,   PI3K/Akt↓, 1,   cl‑PPARα↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   p‑Akt↓, 2,   Apoptosis?, 1,   Apoptosis↑, 9,   BAD↓, 1,   BAD↑, 1,   Bak↓, 1,   BAX↑, 12,   BAX⇅, 1,   Bax:Bcl2↑, 2,   Bcl-2↓, 10,   BID↑, 1,   Casp↑, 2,   Casp3↓, 1,   Casp3↑, 9,   cl‑Casp3↑, 3,   Casp7↑, 1,   Casp8↑, 5,   cl‑Casp8↑, 1,   Casp9↑, 6,   cl‑Casp9↑, 3,   p‑Chk2↑, 1,   Cyt‑c↑, 6,   Cyt‑c↝, 1,   Diablo↑, 1,   DR4↑, 1,   DR5↑, 1,   FADD↑, 2,   Fas↑, 2,   FasL↑, 1,   FasL⇅, 1,   Ferroptosis↑, 1,   hTERT/TERT↓, 2,   iNOS↓, 2,   JNK↓, 2,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 3,   MDM2↓, 2,   MDM2↑, 1,   MOMP↓, 1,   NICD↓, 1,   oncosis↑, 1,   p27↑, 3,   p38↓, 1,   p38↑, 1,   survivin↓, 8,   Telomerase↓, 2,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 3,   Sp1/3/4↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   HATs↓, 1,   pRB↑, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 1,   ER Stress↓, 1,   ER Stress↑, 3,   GRP78/BiP?, 1,   GRP78/BiP↑, 1,   GRP78/BiP↝, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B-II↑, 1,   SESN2↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 7,   DNMTs↓, 1,   HR↓, 1,   MGMT↓, 1,   p16↑, 2,   P53↑, 7,   PARP↑, 2,   cl‑PARP↑, 6,   PCNA↓, 4,   RAD51↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 3,   CDK4↓, 2,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 6,   cycE/CCNE↓, 2,   cycE1↓, 1,   E2Fs↓, 2,   P21↑, 3,   TumCCA↓, 1,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD44↓, 2,   cFos↓, 1,   cMET↓, 1,   CSCs↓, 2,   EMT↓, 2,   EpCAM↓, 2,   ERK↓, 5,   FGF↓, 1,   FOXO↑, 1,   FOXO3↝, 1,   Gli1↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   IGFR↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   NOTCH1↓, 3,   OCT4↓, 2,   PI3K↓, 3,   PTEN↑, 1,   RAS↓, 2,   SOX2↓, 1,   STAT3↓, 2,   STAT3↑, 1,   TAZ↓, 1,   TOP2↓, 1,   TumCG↓, 3,   Wnt↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AntiAg↑, 1,   AP-1↓, 2,   Ca+2↑, 3,   Cdc42↑, 1,   CDK4/6↓, 1,   CEA↓, 1,   E-cadherin↑, 5,   FAK↓, 3,   ITGB1↑, 1,   Ki-67↓, 1,   MMP1↓, 1,   MMP2↓, 15,   MMP7↓, 2,   MMP9↓, 15,   MMPs↓, 4,   N-cadherin↓, 3,   NCAM↑, 1,   PDGF↓, 1,   PKCδ↓, 1,   RECK↑, 2,   Snail↓, 1,   TET1↑, 1,   TGF-β↓, 1,   TIMP1↑, 8,   TIMP2↑, 25,   TIMP3↑, 2,   TumCA↓, 1,   TumCI↓, 8,   TumCMig↓, 6,   TumCP↓, 9,   TumMeta↓, 8,   uPA↓, 4,   uPAR↓, 2,   VCAM-1↓, 1,   VEGFR1↓, 3,   Vim↓, 1,   ZEB2↓, 1,   β-catenin/ZEB1↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 10,   EGFR↓, 3,   EGFR↑, 1,   p‑EGFR↓, 1,   EPR↑, 1,   Hif1a↓, 2,   KDR/FLK-1↓, 1,   NO↓, 1,   VEGF↓, 11,   VEGFR2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 9,   CXCR2↓, 1,   CXCR4↓, 3,   IFN-γ↓, 1,   IKKα↓, 2,   IKKα↑, 1,   IL1↓, 1,   IL6↓, 3,   IL8↓, 2,   Inflam↓, 1,   MIP2↓, 1,   NF-kB↓, 10,   NF-kB↑, 1,   p‑NF-kB↑, 1,   PGE2↓, 2,   TNF-α↓, 3,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 6,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 7,   Dose↝, 4,   eff↓, 1,   eff↑, 9,   Half-Life↓, 1,   MDR1↓, 2,   RadioS↑, 2,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 1,   AR↓, 1,   CEA↓, 1,   EGFR↓, 3,   EGFR↑, 1,   p‑EGFR↓, 1,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 2,   IL6↓, 3,   Ki-67↓, 1,   LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 6,   AntiDiabetic↑, 1,   antiNeop↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 2,   chemoPv↑, 1,   hepatoP↑, 2,   neuroP↑, 1,   OS↑, 1,   TumVol↓, 3,  
Total Targets: 258

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   AntiBio↑, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 8,   Catalase↑, 5,   GPx↑, 3,   GSH↑, 3,   GSR↑, 1,   GSTs↑, 2,   HO-1↑, 1,   Keap1↑, 1,   lipid-P↓, 5,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 7,   SOD↑, 5,   TBARS↓, 1,   uricA↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   LDH↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   Cyt‑c↓, 1,   iNOS↓, 3,   MAPK↓, 1,   p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↑, 1,   mTOR↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   MMP-10↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 2,   MMP9↓, 2,   PKCδ↓, 1,   Rac1↑, 1,   TIMP1↓, 1,   TIMP1↑, 1,   TIMP2↑, 3,   uPA↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   COX2↓, 4,   CRP↓, 1,   ICAM-1↓, 1,   IFN-γ↑, 1,   IL1↓, 1,   IL12↓, 1,   IL1β↓, 4,   IL6↓, 4,   IL6↑, 1,   Imm↑, 1,   Inflam↓, 7,   NF-kB↓, 1,   TLR4↑, 1,   TNF-α↓, 6,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 3,   BChE↓, 1,   BDNF↑, 2,   NGF↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,   BACE↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 9,   eff↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   BP↓, 1,   creat↓, 1,   CRP↓, 1,   IL6↓, 4,   IL6↑, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 5,   cognitive↑, 2,   hepatoP↑, 2,   memory↑, 2,   motorD↑, 1,   neuroP↓, 1,   neuroP↑, 4,   Pain↓, 2,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 2,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Bacteria↓, 1,   CD8+↑, 1,  
Total Targets: 102

Scientific Paper Hit Count for: TIMP2, Tissue Inhibitor of Metalloproteinases-2
3 Betulinic acid
3 Eugenol
3 Lycopene
2 Artemisinin
2 Nimbolide
2 Quercetin
2 Resveratrol
1 Allicin (mainly Garlic)
1 Ashwagandha(Withaferin A)
1 α-Bisabolol / Chamomile oil
1 Carvacrol
1 Chrysin
1 EGCG (Epigallocatechin Gallate)
1 Luteolin
1 Magnetic Field Rotating
1 Magnetic Fields
1 Naringin
1 Silymarin (Milk Thistle) silibinin
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:308  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page